Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ROP COV-19
- Development stage
- Preclinical
- Lead developer
- Oxford Vacmedix
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
ROP COV-19 is a therapeutic vaccine candidate being developed by Oxford Vacmedix for the treatment of COVID-19. It utilizes the company's proprietary Recombinant Overlapping Peptide (ROP) platform technology, which is designed to produce long, overlapping peptides that encompass the entire sequence of a target antigen. This approach aims to stimulate a broad and potent immune response, involving both T-cell and B-cell activation, to target and eliminate SARS-CoV-2. As a therapeutic vaccine, it is intended to treat existing infections rather than provide prophylactic protection. The program is currently in the preclinical stage of development.
Beyond the preview
Go deeper on ROP COV-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ROP COV-19.